As outlined before, the analyzed cohort of HR−/HER2− patients included both true HR−/HER2− tumor biology and a significant number of patients with putative HR+ and/or HER2+ tumor biology who did not receive adequate breast cancer treatment. This evidence concerns the gene ERBB2 and neoplasm.